Quinn Sievers's Avatar

Quinn Sievers

@quinnsievers.bsky.social

Instructor in Lymphoma at Memorial Sloan Kettering and postdoc in the Abdel-Wahab and Vinogradova labs | Big problems, small molecules πŸ³οΈβ€πŸŒˆ

191 Followers  |  154 Following  |  293 Posts  |  Joined: 17.11.2024
Posts Following

Posts by Quinn Sievers (@quinnsievers.bsky.social)

Could you comment on which agencies and awards this data comes from? I’m (selfishly) interested in whether this data also reflects K award rates.

07.03.2026 16:36 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Excited to share our new preprint: β€œA post-translational regulatory map of chronic antigen-driven human T cell dysfunction.”! www.biorxiv.org/content/10.6...

07.03.2026 15:40 β€” πŸ‘ 6    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0

Go get β€˜em @warren.senate.gov

07.03.2026 16:14 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Exclusive | FDA’s Controversial Vaccines Chief Will Leave the Agency Dr. Vinay Prasad will depart in April, after a year leading the division that approves vaccines and biotech drugs.

Vinay Prasad is leaving FDA (again). www.wsj.com/health/healt...

06.03.2026 22:32 β€” πŸ‘ 40    πŸ” 7    πŸ’¬ 3    πŸ“Œ 1
Preview
Collective intelligence for AI-assisted chemical synthesis - Nature A tool based on the Llama-3.1-8B-Instruct architecture called MOSAIC (Multiple Optimized Specialists for AI-assisted Chemical Prediction) is described, allowing chemists to use the collective intellig...

www.nature.com/articles/s41...

05.03.2026 18:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Ohh, awesome! I was actually wondering about this exact thing recently. It's super helpful to have data to answer the question.

04.03.2026 19:54 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

Very excited to have been awarded a Cancer Grand Challenge grant as part of team REWIRE-CAN @cancergrand.bsky.social to develop new approaches to combat cancer #plasticity.
Our goal: to see all #colorectalcancer patients become colorectal cancer survivors.

04.03.2026 15:14 β€” πŸ‘ 36    πŸ” 2    πŸ’¬ 3    πŸ“Œ 0
Post image

Congratulations to MSK's Dr. Andrea Cercek and Dr. Luis Diaz for being accepted into Round 1 of @statnews.com's #STATMadness. Vote for their team now: https://bit.ly/3FfcuRu

03.03.2026 20:35 β€” πŸ‘ 6    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

Congratulations to MSK's Dr. Viviane Tabar and Dr. Lorenz Studer for being accepted into Round 1 of @statnews.com's #STATMadness. Vote for their team now: https://bit.ly/3FfcuRu

03.03.2026 20:33 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
Preventive vaccines for hereditary cancer syndromes - Nature Medicine An β€˜off-the-shelf’ neoantigen vaccine shows safety and immunogenicity in individuals with Lynch syndrome, further advancing hopes for preventive vaccines for hereditary cancer syndromes.

An β€˜off-the-shelf’ neoantigen #vaccine shows safety and immunogenicity in people with #Lynchsyndrome, advancing hopes for preventive cancer vaccines.
News & Views from Zsofia Stadler, Yonina Murciano-Goroff @ Memorial Sloan Kettering Cancer Center
https://www.nature.com/articles/s41591-026-04248-2

03.03.2026 18:30 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Preview
T-cell Engagers for Autoimmune Disease: Ken Song on The Long Run - TimmermanReport.com Ken Song is today’s guest on The Long Run. First things first, this episode was recorded before news broke that Candid Therapeutics went public via a reverse merger with RallyBio. But I must say, that...

T-cell engagers for autoimmune disease. Listen to Ken Song, CEO of San Diego-based Candid Therapeutics, on The Long Run podcast. Sponsored by @alphasenseinc.bsky.social & Dash Bio. timmermanreport.com/2026/03/t-ce...

03.03.2026 14:07 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

we did an immunofluorescence experiment for T cells. if you zoom in you can see it worked (cells are stained) but we had a lot of antibody aggregates (super bright blobs that don't seem to be cells- some not even on the tissue).

any tips on how to avoid having such aggregates?

03.03.2026 18:15 β€” πŸ‘ 5    πŸ” 4    πŸ’¬ 3    πŸ“Œ 0

YES

03.03.2026 18:25 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Degrons and degradation signals beyond short linear motifs - Nature Chemical Biology Degrons are degradation signals in target proteins to direct recognition and degradation by the ubiquitin–proteasome system. Wang et al. introduce degrons of different types, with an emphasis on high-...

www.nature.com/articles/s41...

02.03.2026 10:58 β€” πŸ‘ 16    πŸ” 5    πŸ’¬ 0    πŸ“Œ 0

Reposting for our team riding in @cycleforsurvival.bsky.social
this Friday. Still time to donate using the link below! Every dollar goes to support patient-facing rare cancer research! Donate here: shorturl.at/U92Sc

02.03.2026 15:43 β€” πŸ‘ 2    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Preview
Opinion | The glamour of the front line (Published 2006)

"There is a dirty little secret in journalism: War reporting is the fastest way to get ahead."

My 2006 Op-ed on why war (tragically) remains irresistible to news junkies and journalists: "The Glamour of the Front Line."

www.nytimes.com/2006/02/06/o...

01.03.2026 21:29 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
A line graph showing NSF grant awards made through 2/27/26 for fiscal year 2026 compared with grant awards for fiscal years 2021-2025.

A line graph showing NSF grant awards made through 2/27/26 for fiscal year 2026 compared with grant awards for fiscal years 2021-2025.

NSF Update (Awards through 2/27/26)

Directorates to follow

1/10

01.03.2026 14:48 β€” πŸ‘ 669    πŸ” 446    πŸ’¬ 28    πŸ“Œ 118

β€œThe pattern is clear: When legislation fails, proceed administratively. Close offices through personnel actions. Eliminate review structures through internal reorganization. Redirect missions through policy directives.”

28.02.2026 17:56 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

β€œWeeks after Congress rejected the Trump administration’s proposed cuts to NIH and passed a full-year budget on February 3, 2026, the White House Office of Management and Budget (OMB) has refused to authorize release of the funds.”

28.02.2026 17:55 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

I learned a lot reading this. Two important quotes:

28.02.2026 17:54 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Preview
I’m So Used to Gay Tragedies That I Almost Missed Romance

Whew, Wesley Morris on Heated Rivalry is worth your time.

27.02.2026 16:12 β€” πŸ‘ 26    πŸ” 4    πŸ’¬ 2    πŸ“Œ 2
Post image

This week's cover @thelancet.com

26.02.2026 23:48 β€” πŸ‘ 3117    πŸ” 1457    πŸ’¬ 44    πŸ“Œ 80
Post image

What about feedback/comments? Authors clearly want and are getting feedback on articles, but it’s mostly private, via email. Cultural change is needed for this to move to the public comment section, and it will always be distributed (social media, etc.) 4/n

26.02.2026 16:09 β€” πŸ‘ 19    πŸ” 9    πŸ’¬ 2    πŸ“Œ 1

New version of our preprint on bioRxiv about bioRxiv up. Now that’s what I call a revision – 6 years after the first version!
It has new data about our progress and highlights from a massive user survey. 1/n
www.biorxiv.org/content/10.1...

26.02.2026 16:05 β€” πŸ‘ 78    πŸ” 43    πŸ’¬ 1    πŸ“Œ 4
Post image

We made FLIP2, a protein fitness benchmark spanning seven new datasets, including enzymes, protein-protein interactions, and light-sensitive proteins, as well as splits that measure generalization relevant to real-world protein engineering campaigns.

25.02.2026 21:25 β€” πŸ‘ 51    πŸ” 15    πŸ’¬ 1    πŸ“Œ 1
Preview
Clinical-grade autonomous cytopathology through whole-slide edge tomography - Nature This study presents a clinical-grade autonomous pipeline combining high-resolution whole-slide tomography, edge computing and artificial intelligence, achieving high accuracy in cervical cytology and ...

www.nature.com/articles/s41...

26.02.2026 02:30 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Panel A: A figure showing the change in the sum of diameters of the target lesions across tumor types. 

Panel B: A figure showing the overall duration of treatment and the time to first response observed in 46 patients treated with a dose in the observed efficacious-dose range who had wild-type KRAS.

Panel A: A figure showing the change in the sum of diameters of the target lesions across tumor types. Panel B: A figure showing the overall duration of treatment and the time to first response observed in 46 patients treated with a dose in the observed efficacious-dose range who had wild-type KRAS.

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P

#MedSky #Oncology

25.02.2026 22:10 β€” πŸ‘ 7    πŸ” 4    πŸ’¬ 1    πŸ“Œ 1

This seems super important for endogenous lineage tracing!!

β€œIn vivo lineage tracing across human tissues using methylation barcodes in the protocadherin gene cluster”

www.biorxiv.org/content/10.6...

24.02.2026 23:42 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

And that would be β€œfed” to BlueSky when it β€œasks” for a thumbnail? I have no idea how this works haha.

24.02.2026 20:12 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Ah I see. Perhaps on submission you could have the option of designating a figure for the thumbnail for social media posts?

24.02.2026 20:04 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0